
Sign up to save your podcasts
Or


In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration's authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.
By American Academy of Neurology4.7
283283 ratings
In the first segment, Dr. Jeffrey Ratliff talks with Dr. Franziska Hopfner about her paper on the use of ß2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. In the second part of the podcast, Dr. Jason Crowell focuses his discussion with Dr. Jerzy Szaflarski on his JAMA Neurology paper on the US Food and Drug Administration's authorization of the first cannabis-derived pharmaceutical. You can read the paper here: https://jamanetwork.com/journals/jamaneurology/article-abstract/2714720.

321 Listeners

496 Listeners

50 Listeners

290 Listeners

3,333 Listeners

13 Listeners

1,154 Listeners

22 Listeners

195 Listeners

361 Listeners

515 Listeners

132 Listeners

179 Listeners

369 Listeners

79 Listeners